Arrowhead reports interim Phase 1/2a results for ARO-MAPT, showing 73% spinal fluid tau suppression in Alzheimer's study

Arrowhead Pharmaceuticals announced interim results from its ongoing Phase 1/2a study of ARO-MAPT, an investigational subcutaneous RNAi therapeutic for Alzheimer's disease and other tauopathies. The company said the data validate its brain delivery platform and show significant tau suppression, cutting spinal fluid tau by a mean of 73% at the highest dose in healthy volunteers, with reductions holding 90 days after the last injection.

Detected & updated continuously · Source: Nebula